What is the 13F Pro Quality Score for MDXG?

13F Pro ranks MIMEDX GROUP, INC. (MDXG) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MDXG's current score at https://13fpro.ai/research/MDXG (free sign-up required for the full ranking).

Which hedge funds own the most MDXG stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MDXG include Essex Woodlands Management,, BlackRock,, Trigran Investments,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MDXG as soon as new 13F filings post.

Where does 13F Pro source MDXG data?

All MIMEDX GROUP, INC. fundamentals and ownership data come directly from SEC EDGAR. MIMEDX GROUP, INC. files with the SEC under CIK 1376339. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MDXG in?

MIMEDX GROUP, INC. (MDXG) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MDXG research updated on 13F Pro?

MDXG's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MIMEDX GROUP, INC.(MDXG)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1376339 MDXG stock profile & AI dashboard →

13F Pro Quality Score

55.6/100

Rank #1,149 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

54.6/100

Profitability

41.8/100

Balance Sheet

77.1/100

Earnings Quality

74.2/100

Free Cash Flow

71.6/100

Institutional Flow

80.5/100

Revenue Scale

32.2/100

Dilution Risk

29.3/100

MDXG Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MIMEDX GROUP, INC. (MDXG), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MDXG at 55.6/100 on a 32-signal composite quality model, placing it at rank #1,149 of 2,879 stocks — the top half of the AI-ranked universe. MDXG scores in the top quartile across institutional flow (80.5), balance sheet strength (77.1). Areas of concern include revenue scale (32.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 29.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), MIMEDX GROUP, INC. reports quarterly revenue of $59.0M, net income of $-10.9M, free cash flow of $1.9M. Top institutional holders of MDXG by reported 13-F value include Essex Woodlands Management,, BlackRock,, Trigran Investments,, based on the most recent SEC filings. MDXG trades on the Nasdaq exchange and files with the SEC under CIK 1376339. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDXG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MIMEDX GROUP, INC. directly from SEC EDGAR. MIMEDX GROUP, INC.'s 13F Pro composite quality score has ranged between 8 and 82 since 2021, currently 55.6 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about MIMEDX GROUP, INC.

Quirks, history, and lore behind MDXG — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in Georgia.
2
The Numbers
Annual revenue in the range of $250–300 million, built almost entirely on products derived from donated human tissue — a supply chain you can't exactly order from a factory.
3
The History
Founded in the late 1990s, it carved out a niche in regenerative medicine — specifically processing and distributing amniotic tissue grafts for wound and surgical care.
4
The Secret
Its core products come from placental and amniotic membranes — donated after healthy births — which are processed into grafts that help chronic wounds heal when almost nothing else will.
5
The Lore
The company spent years battling Medicare reimbursement disputes and securities lawsuits, emerging leaner and refocused — proving that even regenerative medicine has scar tissue.
6
The Giveaway
Its ticker is MDXG, its full name contains the word MiMedx, and it is the leading commercial supplier of amniotic allografts to wound care and surgical markets across the U.S.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$59.0M

Net Income

Q1 2026

$-10.9M

Free Cash Flow

Q1 2026

$1.9M

D/E Ratio

Q1 2026

0.07

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+20.0% YoY

$418.6MFY 2025

FY22 $267.8MFY23 $321.5MFY24 $348.9MFY25 $418.6M

Net Income

+14.5% YoY

$48.6MFY 2025

FY22 $-30.2MFY23 $58.2MFY24 $42.4MFY25 $48.6M

Operating Income

+8.5% YoY

$63.9MFY 2025

FY22 $-14.7MFY23 $37.1MFY24 $58.9MFY25 $63.9M

EPS (Diluted)

+14.3% YoY

$0.32FY 2025

FY22 $-0.33FY23 $0.37FY24 $0.28FY25 $0.32

Total Assets

+29.8% YoY

$342.7MFY 2025

FY22 $171.4MFY23 $239.0MFY24 $263.9MFY25 $342.7M

Total Debt

-2.5% YoY

$19.5MFY 2025

FY22 $50.0MFY23 $51.0MFY24 $20.0MFY25 $19.5M

Op. Cash Flow

+11.8% YoY

$74.0MFY 2025

FY22 $-17.9MFY23 $26.8MFY24 $66.2MFY25 $74.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$418.6M +20.0%	$348.9M +8.5%	$321.5M +20.0%	$267.8M +10.7%	$242.0M -2.5%	$248.2M
Net Income	$48.6M +14.5%	$42.4M -27.2%	$58.2M +292.8%	$-30.2M -193.6%	$-10.3M +79.1%	$-49.3M
Operating Income	$63.9M +8.5%	$58.9M +58.6%	$37.1M +352.0%	$-14.7M -108.9%	$-7.1M +84.5%	$-45.4M
EPS (Diluted)	$0.32 +14.3%	$0.28 -24.3%	$0.37 +212.1%	$-0.33 -120.0%	$-0.15 +80.5%	$-0.77
Total Assets	$342.7M +29.8%	$263.9M +10.4%	$239.0M +39.4%	$171.4M -8.8%	$187.9M -7.0%	$202.0M
Total Debt	$19.5M -2.5%	$20.0M -60.8%	$51.0M +2.0%	$50.0M +0.0%	$50.0M +0.0%	$50.0M
Operating Cash Flow	$74.0M +11.8%	$66.2M +147.2%	$26.8M +249.6%	$-17.9M -802.8%	$-2.0M +93.5%	$-30.3M

AI Insight: MDXG Financial Trends

MIMEDX revenue collapsed 50% in Q1 2026 to $59M from $118M in Q4 2025, turning operating income negative for the first time.

• Revenue fell sharply from $118M in Q4 2025 to $59M in Q1 2026, erasing prior quarter gains.

• Operating income turned negative at -$16M in Q1 2026 after consistent profitability through Q4 2025.

• Operating cash flow dropped from $25M in Q4 2025 to just $2M in Q1 2026.

• Total debt remained stable around $18-20M while equity grew from $168M to $243M over eight quarters.

⚠ Net income swung to -$11M loss in Q1 2026 from consistent profitability in prior periods.

⚠ Sequential revenue volatility with 36% growth in Q3 2025 followed by 50% decline in Q1 2026.

AI Insight: MDXG Ratio Trends

MIMEDX profitability collapsed in Q1 2026 with operating margin plunging from 17.8% to -27.2%.

• Operating margin deteriorated from 17.8% in Q4 2025 to -27.2% in Q1 2026.

• ROE turned negative to -17.9% in Q1 2026 after reaching 28.0% in Q3 2025.

• ROIC crashed to -24.6% in Q1 2026 from 30.5% in Q4 2025.

• Debt-to-equity ratio improved from 0.11 in Q3 2024 to 0.07 in Q1 2026.

⚠ Profitability recovery timeline after severe Q1 2026 losses across all metrics.

⚠ Whether Q1 2026 losses reflect seasonal patterns or structural deterioration.

Get alerted when MDXG's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MIMEDX GROUP, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MDXG

Essex Woodlands Management, Inc.
$111.4M28,195,249 sh
BlackRock, Inc.
$47.0M11,911,300 sh
Trigran Investments, Inc.
$28.3M7,175,109 sh
VANGUARD CAPITAL MANAGEMENT LLC
$20.4M5,166,006 sh
STATE STREET CORP
$20.0M5,056,801 sh
PARADIGM CAPITAL MANAGEMENT INC/NY
$13.5M3,410,300 sh
Nantahala Capital Management, LLC
$13.4M3,397,299 sh
RENAISSANCE TECHNOLOGIES LLC
$11.9M3,019,871 sh
GEODE CAPITAL MANAGEMENT, LLC
$11.4M2,881,159 sh
First Light Asset Management, LLC
$11.2M2,842,892 sh

Fund	Value	Shares
Essex Woodlands Management, Inc.	$111.4M	28,195,249
BlackRock, Inc.	$47.0M	11,911,300
Trigran Investments, Inc.	$28.3M	7,175,109
VANGUARD CAPITAL MANAGEMENT LLC	$20.4M	5,166,006
STATE STREET CORP	$20.0M	5,056,801
PARADIGM CAPITAL MANAGEMENT INC/NY	$13.5M	3,410,300
Nantahala Capital Management, LLC	$13.4M	3,397,299
RENAISSANCE TECHNOLOGIES LLC	$11.9M	3,019,871
GEODE CAPITAL MANAGEMENT, LLC	$11.4M	2,881,159
First Light Asset Management, LLC	$11.2M	2,842,892

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MDXG on your watchlist

Track score changes the day MIMEDX GROUP, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MDXG a good stock to buy?

13F Pro's AI-powered analysis of MIMEDX GROUP, INC. (MDXG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MDXG are available on the MDXG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MDXG?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MDXG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MIMEDX GROUP, INC.'s investment landscape.